IONS Latest Headlines

Ionis Pharmaceuticals (IONS) Gets a Buy from Barclays

at www.tipranks.com (Thu, 23-Jul 5:17 AM)

Arrowhead hits 52-week high as late-stage trial win marks “derisking event”

at seekingalpha.com (Wed, 22-Jul 1:14 PM)

Ionis Maintains Buy Rating as Olezarsen’s sHTG Profile Outshines Rival; $86 Price Target Reaffirmed

at www.tipranks.com (Wed, 22-Jul 10:55 AM)

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

at seekingalpha.com (Wed, 22-Jul 8:11 AM)

These healthcare stocks are trading near oversold levels as earnings season picks up

at seekingalpha.com (Tue, 21-Jul 8:54 AM)

Cathie Wood’s ARK Invest adds another $57M to SpaceX, sells $39M stake in AMD

at seekingalpha.com (Mon, 20-Jul 7:05 AM)

Ionis and Biogen Reveal First Tau Therapy to Show Strong Reductions in Brain and CSF Tau With Clinical Benefit in Early Alzheimer’s Disease

Market Chameleon (Tue, 14-Jul 9:46 AM)

Eplontersen’s Phase 3 ATTR-CM Study Misses Primary Goal—but Monotherapy Signals Potential Benefit in Key Subgroup

Market Chameleon (Thu, 9-Jul 7:05 AM)

Ionis Advances Alzheimer’s Research as Biogen’s Diranersen Shows Historic Reduction in Tau Pathology

Market Chameleon (Thu, 14-May 11:56 AM)

Biogen and Ionis Report First Phase 2 Evidence of Reducing Tau Pathology and Slowing Cognitive Decline in Early Alzheimer’s Disease

Market Chameleon (Thu, 14-May 7:32 AM)

Ionis Boosts 2026 Guidance as TRYNGOLZA Drives Revenue and Major Launches Approach

Market Chameleon (Wed, 29-Apr 9:37 AM)